Evidence-Based Complementary and Alternative Medicine / 2018 / Article / Tab 4

Research Article

A Randomized Double-Blind Placebo-Controlled Trial to Evaluate Prophylactic Effect of Traditional Chinese Medicine Supplementing Qi and Hemostasis Formula on Gastrointestinal Bleeding after Percutaneous Coronary Intervention in Patients at High Risks

Table 4

Comparison between patients with and without ischemic events occurrence.

Ischemic cardiac event occurred (N=8)Ischemic cardiac event absent (N=109)StatisticsP value

Age-1.11(Z)0.2655
Gender-(Fisher)0.0245
Male N(%)6(75.00)36(33.03)
Female N(%)2(25.00)73(66.97)
Weight (kg)-0.40(Z)0.6889
Height (m)0.65(Z)0.5158
SBP (mmHg)1.29(Z)0.1967
HR (beat/min)1.00(Z)0.3175
Smoking2(25.00)38(34.86)-(Fisher)0.7137
Alcohol intake1(12.50)23(21.10)-(Fisher)1.0000
Duration of smoking-1.27(Z)0.2044
CRUSADE score1.70(Z)0.0896
Admitting condition-(Fisher)1.0000
Urgent N(%)4(50.00)55(50.46)
Selective N(%)4(50.00)54(49.54)
Admitting diagnosis0.7641
STEMI N(%)2(25.00)24(22.02)
NSTEMI N(%)3(37.50)25(22.94)
UAP N(%)2(25.00)39(35.78)
SAP N(%)1(12.50)21(19.27)
Medical history
Hypertension N(%)7(87.50)80(73.39)-(Fisher)0.6779
Type-2 DM N(%)6(75.00)59(54.13)-(Fisher)0.2971
Lipid disorder N(%)2(25.00)26(23.85)-(Fisher)1.0000
Chronic heart dysfunction N(%)2(25.00)26(23.85)-(Fisher)1.0000
Chronic kidney dysfunction N(%)4(50.00)27(24.77)-(Fisher)0.2056
Chronic bronchitis N(%)1(12.50)8(7.34)-(Fisher)0.4838
Anemia N(%)0(0.00)4(3.67)-(Fisher)1.0000
Prior cerebrovascular disease N(%)1(12.50)38(34.86)-(Fisher)0.2659
Prior peptic ulcer N(%)1(12.50)7(6.42)-(Fisher)0.4429
PCI access site-(Fisher)0.7330
 Radial artery N(%)5(62.50)76(69.72)
 Femoral artery N(%)3(37.50)31(28.44)
 Both N(%)0(0.00)2(1.83)
Number of diseased vessel0.39(Z)0.6975
 Single N(%)3(37.50)30(27.52)
 Double N(%)0(0.00)31(28.44)
 Multiple N(%)5(62.50)48(44.04)
Part of diseased vessel
 LM N(%)3(37.50)15(13.76)-(Fisher)0.1046
 AD N(%)6(75.00)88(80.73)-(Fisher)0.6548
 CX N(%)5(62.50)63(57.80)-(Fisher)1.0000
 RC N(%)7(87.50)68(62.39)-(Fisher)0.2557
 Others N(%)1(12.50)16(14.68)-(Fisher)1.0000
IABP implantation4(50.00)29(26.61)-(Fisher)0.2191
Temporary cardiac pacemaker implantation 1(12.50)6(5.50)-(Fisher)0.3992
Number of stent implantation0.28(Z)0.7830
TEG
2.09(Z)0.0366
 Inhibition of ADP-2.45(Z)0.0144
 Inhibition of AA1.17(Z)0.2413

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.